Comment
. 2011 Feb;69(2):424; author reply 425.
doi: 10.1002/ana.22257.
Stalevo reduction in dyskinesia evaluation in Parkinson's disease results were expected from a pharmacokinetic viewpoint
- PMID: 21387388
- DOI: 10.1002/ana.22257
Item in Clipboard
Comment
Stalevo reduction in dyskinesia evaluation in Parkinson's disease results were expected from a pharmacokinetic viewpoint
Ann Neurol.
2011 Feb.
No abstract available
Comment on
-
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.Ann Neurol. 2010 Jul;68(1):18-27. doi: 10.1002/ana.22060. Ann Neurol. 2010. PMID: 20582993 Clinical Trial.
Similar articles
-
Fluctuation in plasma entacapone concentrations in accordance with variable plasma levodopa concentrations.Parkinsonism Relat Disord. 2010 Dec;16(10):697-9. doi: 10.1016/j.parkreldis.2010.08.019. Epub 2010 Sep 19. Parkinsonism Relat Disord. 2010. PMID: 20855228 No abstract available.
-
[Therapy for patients with progressive Parkinson's disease].Nihon Naika Gakkai Zasshi. 2003 Aug 10;92(8):1432-7. Nihon Naika Gakkai Zasshi. 2003. PMID: 13677891 Review. Japanese. No abstract available.
-
Rasagiline for motor complications in Parkinson's disease.Lancet. 2005 Mar 12-18;365(9463):914-6. doi: 10.1016/S0140-6736(05)71056-4. Lancet. 2005. PMID: 15766976 No abstract available.
-
Levodopa/carbidopa/entacapone (Stalevo).Neurology. 2004 Jan 13;62(1 Suppl 1):S64-71. doi: 10.1212/wnl.62.1_suppl_1.s64. Neurology. 2004. PMID: 14718682 Clinical Trial.
-
Interventions to achieve tonic exposure to levodopa: delaying or preventing the onset of motor complications.Pharmacotherapy. 1999 Nov;19(11 Pt 2):169S-79S. doi: 10.1592/phco.19.17.169S.30886. Pharmacotherapy. 1999. PMID: 10555945 Review.
Cited by
-
Motor fluctuations and Helicobacter pylori in Parkinson's disease.J Neurol. 2013 Dec;260(12):2974-80. doi: 10.1007/s00415-013-7089-6. Epub 2013 Sep 4. J Neurol. 2013. PMID: 24002418
-
Human COMT over-expression confers a heightened susceptibility to dyskinesia in mice.Neurobiol Dis. 2017 Jun;102:133-139. doi: 10.1016/j.nbd.2017.03.006. Epub 2017 Mar 16. Neurobiol Dis. 2017. PMID: 28315782 Free PMC article.
-
Catechol-O-methyltransferase inhibitors in Parkinson's disease.Drugs. 2015 Feb;75(2):157-74. doi: 10.1007/s40265-014-0343-0. Drugs. 2015. PMID: 25559423 Review.
-
IPX066: a new intermediate-and extended-release carbidopa-levodopa formulation.Neurodegener Dis Manag. 2013 Apr 1;3(2):123-131. doi: 10.2217/nmt.13.4. Neurodegener Dis Manag. 2013. PMID: 24501594 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
